Table 1 Clinical and demographic characteristics of patients with MCL in our cohort
From: Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population
Characteristic | N (%) |
|---|---|
Total | 66 (100) |
Age (years) | |
 Median (range) | 59 (26 to 84) |
  ≥ 60 | 32 (48.5) |
  < 60 | 34 (51.5) |
Sex | |
 Male | 48 (72.7) |
 Female | 18 (27.3) |
Ethnicity | |
 Chinese | 50 (75.8) |
 Malay | 7 (10.6) |
 Indian | 3 (4.55) |
 Others | 6 (13.6) |
Smoking history | |
 Yes | 9 (13.6) |
 No | 57 (86.4) |
B-symptoms | |
 Absent | 45 (68.2) |
 Present | 21 (31.8) |
ECOG performance status | |
 0 | 40 (60.6) |
 1–4 | 26 (39.4) |
Ann Arbor stage | |
 1–2 | 9 (18.2) |
 3–4 | 57 (86.4) |
sMIPI risk | |
 Low | 20 (30.3) |
 Intermediate | 30 (45.5) |
 High | 16 (24.2) |
Bulky disease > 10 cm | |
 Yes | 6 (9.5) |
 No | 57 (90.5) |
Spleen involved | |
 Yes | 20 (30.3) |
 No | 46 (69.7) |
Number of nodal sites | |
 0–3 | 26 (39.4) |
  ≥ 4 | 40 (60.6) |
Extra-nodal involvement | |
 Yes | 54 (81.8) |
 No | 12 (18.2) |
Bone marrow involvement | |
 Positive | 41 (62.1) |
 Negative | 25 (37.9) |
Ki-67 expression (%) | Â |
  > 30 | 22 (47.8) |
  ≤ 30 | 24 (52.2) |
Serum LDH | Â |
 Elevated | 35 (54.7) |
 Not elevated | 29 (45.3) |
Albumin (g/L) | Â |
  < 35 | 18 (27.7) |
  ≥ 35 | 47 (72.3) |
Hemoglobin (g/dL) | Â |
  ≤ 12.4 | 36 (54.5) |
  > 12.4 | 30 (45.5) |
WBC (109 cells/L) | Â |
  > 10 | 19 (28.8) |
  ≤ 10 | 47 (71.2) |